Get started
Agenus Inc.Agenus Inc.Agenus Inc.

Agenus Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

AGEN chart


Full chart

AGEN upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪85.86 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−11.00 USD
Net income (FY)
‪−245.76 M‬ USD
Revenue (FY)
‪156.31 M‬ USD
Shares float
‪22.36 M‬
Beta (1Y)
5.75

Employees


Employees (FY)
389
Change (1Y)
−144 −27.02%
Revenue / Employee (1Y)
‪401.84 K‬ USD
Net income / Employee (1Y)
‪−631.78 K‬ USD

About Agenus Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Garo H. Armen
Website
agenusbio.com
Headquarters
Lexington
Founded
1994
FIGI
BBG000C8SWQ9
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

AGEN news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of AGEN is 3.76 USD — it has decreased by −4.44% in the past 24 hours. Watch Agenus Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Agenus Inc. stocks are traded under the ticker AGEN.
AGEN stock has risen by 12.27% compared to the previous week, the month change is a 27.97% rise, over the last year Agenus Inc. has showed a −69.92% decrease.
We've gathered analysts' opinions on Agenus Inc. future price: according to them, AGEN price has a max estimate of 11.00 USD and a min estimate of 6.00 USD. Watch AGEN chart and read a more detailed Agenus Inc. stock forecast: see what analysts think of Agenus Inc. and suggest that you do with its stocks.
AGEN reached its all-time high on Feb 7, 2000 with the price of 8,580.00 USD, and its all-time low was 2.50 USD and was reached on Nov 19, 2024. View more price dynamics on AGEN chart.
See other stocks reaching their highest and lowest prices.
AGEN stock is 9.91% volatile and has beta coefficient of 5.75. Track Agenus Inc. stock price on the chart and check out the list of the most volatile stocks — is Agenus Inc. there?
Today Agenus Inc. has the market capitalization of ‪85.86 M‬, it has decreased by −11.13% over the last week.
Yes, you can track Agenus Inc. financials in yearly and quarterly reports right on TradingView.
Agenus Inc. is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
AGEN earnings for the last quarter are −3.08 USD per share, whereas the estimation was −2.31 USD resulting in a −33.12% surprise. The estimated earnings for the next quarter are −2.64 USD per share. See more details about Agenus Inc. earnings.
Agenus Inc. revenue for the last quarter amounts to ‪25.11 M‬ USD, despite the estimated figure of ‪33.48 M‬ USD. In the next quarter, revenue is expected to reach ‪31.99 M‬ USD.
AGEN net income for the last quarter is ‪−66.39 M‬ USD, while the quarter before that showed ‪−53.08 M‬ USD of net income which accounts for −25.07% change. Track more Agenus Inc. financial stats to get the full picture.
No, AGEN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 24, 2025, the company has 389.00 employees. See our rating of the largest employees — is Agenus Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Agenus Inc. EBITDA is ‪−85.52 M‬ USD, and current EBITDA margin is −93.73%. See more stats in Agenus Inc. financial statements.
Like other stocks, AGEN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Agenus Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Agenus Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Agenus Inc. stock shows the sell signal. See more of Agenus Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.